Evelo Biosciences
Evelo Biosciences's latest marketcap:
As of 07/30/2025, Evelo Biosciences's market capitalization has reached $9,491. According to our data, Evelo Biosciences is the 49535th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 9,491 |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -82,349,000 |
| Shares Out | 18.98 M |
| EPS (ttm) | -9.65 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/08/2025 |
Evelo Biosciences's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/30/2025 | $9,491 | 0% | 49535 |
| 12/30/2024 | $9,491 | -99.19% | 48358 |
| 12/29/2023 | $1.17 M | -99.34% | 46683 |
| 12/30/2022 | $176.48 M | -45.62% | 44942 |
| 12/31/2021 | $324.5 M | -41.89% | 42908 |
| 12/31/2020 | $558.43 M | 328.67% | 39677 |
| 12/31/2019 | $130.27 M | -68.48% | 36967 |
| 12/31/2018 | $413.32 M | 35570 |
Company Profile
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing innovative oral medicines that target immune cells in the small intestine to produce systemic effects.
Key Product Candidates
- EDP1815: A whole-microbe product candidate that has completed a Phase 2 trial for psoriasis and is currently in Phase 2 clinical trials for atopic dermatitis.
- EDP1867: A non-live pharmaceutical preparation derived from a single strain of Veillonella parvula, currently in Phase 1b clinical trials.
- EDP2939: An investigational oral biologic with potential applications in treating inflammatory diseases.
- EDP1908: A promising product candidate focused on oncology.
Company Background
Founded in 2014, Evelo Biosciences, Inc. is headquartered in Cambridge, Massachusetts, and continues to pioneer novel therapeutic approaches in immunology and inflammation.
Frequently Asked Questions
-
What is Evelo Biosciences's (OTC-EVLO) current market cap?As of 07/30/2025, Evelo Biosciences (including the parent company, if applicable) has an estimated market capitalization of $9,491 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Evelo Biosciences (OTC-EVLO) rank globally by market cap?Evelo Biosciences global market capitalization ranking is approximately 49535 as of 07/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.